Literature DB >> 29608020

Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia.

So Inamura1,2, Hideaki Ito1, Tomochika Shinagawa1,2, Manami Tsutsumiuchi1,2, Minekatsu Taga1,2, Motohiro Kobayashi2, Osamu Yokoyama1.   

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) is a common urologic disease in older men. Prostatic inflammation research has focused on the magnitude of inflammation; its location has received little attention. We investigated whether the anatomic location of prostatic inflammation is related to the severity of lower urinary tract symptoms (LUTS), measured subjectively and objectively.
METHODS: We retrospectively analyzed hematoxylin+eosin-stained tissue specimens from 179 BPH patients who underwent transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP). Chronic prostatic inflammation was assessed by the grade (lymphocyte density), extent (lymphocyte distribution), and location of inflammation. Each inflammation-finding type was evaluated in relation to these clinical parameters: age, prostate volume, prostate-specific antigen (PSA) value, body mass index (BMI), the frequency of acute urinary retention (AUR) episodes, the international prostatic symptom score (IPSS), and urodynamic study results.
RESULTS: The magnitude and extent of inflammation were not associated with any clinical parameters. We classified the BPH patients into stromal (n = 72) versus non-stromal (n = 105) groups based on their inflammation's dominant location. The stromal group's prostatic volume was significantly larger than the non-stromal group's (63.8 vs 53.8 mL; P = 0.032). AUR episodes were more significantly frequent in the stromal group (36.1% vs 11.4%; P = 0.006). Between-group differences in storage parameters (ie, maximum cystometric capacity) in the urodynamic study were not significantly different. Voiding parameters differed significantly between the stromal and non-stromal groups: maximum detrusor pressure (maxPdet) (116.8 vs 94.5 cmH2 O, P = 0.014), Pdet at the maximum flow rate (Qmax) (95.8 vs 75.4 cmH2 O, P = 0.014), and the bladder outlet obstruction index (BOOI) (78.5 vs 56.3, P = 0.014). The stromal group's Qmax was significantly lower than the non-stromal group's (7.3 vs 9.8 mL/s, P = 0.004).
CONCLUSIONS: The location of inflammation in the prostate might be an important factor affecting the severity of LUTS, especially voiding dysfunction.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  bladder outlet obstruction; international prostatic symptom score; pressure flow study; prostatic stromal inflammation; urodynamic study

Mesh:

Year:  2018        PMID: 29608020     DOI: 10.1002/pros.23518

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  9 in total

1.  Comparison of thermal injury depth of the prostate between plasma kinetic electrode, holmium laser, green light laser and Nd:YAG laser.

Authors:  Meng Gu; Yanbo Chen; Ming Zhan; Chong Liu; Zhikang Cai; Qi Chen; Zhong Wang
Journal:  Int Urol Nephrol       Date:  2021-01-22       Impact factor: 2.370

2.  Inflammation, Voiding and Benign Prostatic Hyperplasia Progression.

Authors:  Granville L Lloyd; William A Ricke; Kevin T McVary
Journal:  J Urol       Date:  2019-05       Impact factor: 7.450

3.  Cross-organ sensitization between the prostate and bladder in an experimental rat model of lipopolysaccharide (LPS)-induced chronic pelvic pain syndrome.

Authors:  Ozgu Aydogdu; Pinar Uyar Gocun; Patrik Aronsson; Thomas Carlsson; Michael Winder
Journal:  BMC Urol       Date:  2021-08-21       Impact factor: 2.264

Review 4.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

5.  Serum interleukin 6 and acute urinary retention in elderly men with benign prostatic hyperplasia in China: a cross-sectional study.

Authors:  Di Wu; Zhi-En Shi; Ding Xu; Yu Wu; Su-Bo Qian; Jun Qi
Journal:  Transl Androl Urol       Date:  2021-01

Review 6.  Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging.

Authors:  Dehong Cao; Ruonan Sun; Lei Peng; Jinze Li; Yin Huang; Zeyu Chen; Bo Chen; Jin Li; Jianzhong Ai; Lu Yang; Liangren Liu; Qiang Wei
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

7.  Serum omentin-1 level in patients with benign prostatic hyperplasia.

Authors:  Haiqing He; Shuiqing Wu; Jun Hao; Long Wang; Kai Ai; Xuan Zhu; Ran Xu; Xiaokun Zhao; Yinhuai Wang; Zhaohui Zhong
Journal:  BMC Urol       Date:  2020-05-06       Impact factor: 2.264

Review 8.  Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia.

Authors:  Yu Tong; Ren-Yuan Zhou
Journal:  Mediators Inflamm       Date:  2020-10-28       Impact factor: 4.711

9.  Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia.

Authors:  Marta Tenuta; Maria G Tarsitano; Paola Mazzotta; Livia Lucchini; Franz Sesti; Giorgio Fattorini; Carlotta Pozza; Valerio Olivieri; Fabio Naro; Daniele Gianfrilli; Andrea Lenzi; Andrea M Isidori; Riccardo Pofi
Journal:  Andrology       Date:  2020-03-16       Impact factor: 3.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.